Additionally, immunohistochemical detection of Ki-67, performed to evaluate tumor viability and proliferation, demonstrated a significant dose-dependent decrease in the Ki-67 expression rate in the SBO-treatment groups (Figure 6B). The gene discussed is MKI67; the disease is neoplasm.